183 related articles for article (PubMed ID: 34312726)
1. Improving cost-effectiveness of endoscopic surveillance for Barrett's esophagus by reducing low-value care: a review of economic evaluations.
Vissapragada R; Bulamu NB; Brumfitt C; Karnon J; Yazbeck R; Watson DI
Surg Endosc; 2021 Nov; 35(11):5905-5917. PubMed ID: 34312726
[TBL] [Abstract][Full Text] [Related]
2. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
3. Is endoscopic surveillance for non-dysplastic Barrett's esophagus cost-effective? Review of economic evaluations.
Hirst NG; Gordon LG; Whiteman DC; Watson DI; Barendregt JJ
J Gastroenterol Hepatol; 2011 Feb; 26(2):247-54. PubMed ID: 21261712
[TBL] [Abstract][Full Text] [Related]
4. Does Risk of Progression from Barrett's Esophagus to Esophageal Adenocarcinoma Change Based on the Number of Non-dysplastic Endoscopies?
Kunzmann AT; Coleman HG; Johnston BT; Turkington RC; McManus D; Anderson LA; Thrift AP
Dig Dis Sci; 2021 Jun; 66(6):1965-1973. PubMed ID: 32734400
[TBL] [Abstract][Full Text] [Related]
5. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.
Gaddam S; Singh M; Balasubramanian G; Thota P; Gupta N; Wani S; Higbee AD; Mathur SC; Horwhat JD; Rastogi A; Young PE; Cash BD; Bansal A; Vargo JJ; Falk GW; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2013 Sep; 145(3):548-53.e1. PubMed ID: 23714382
[TBL] [Abstract][Full Text] [Related]
6. Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective?
Inadomi JM; Saxena N
Dig Dis Sci; 2018 Aug; 63(8):2094-2104. PubMed ID: 29948571
[TBL] [Abstract][Full Text] [Related]
7. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
[TBL] [Abstract][Full Text] [Related]
8. Optimizing Management of Patients With Barrett's Esophagus and Low-Grade or No Dysplasia Based on Comparative Modeling.
Omidvari AH; Ali A; Hazelton WD; Kroep S; Lee M; Naber SK; Lauren BN; Ostvar S; Richmond E; Kong CY; Rubenstein JH; Lansdorp-Vogelaar I; Luebeck G; Hur C; Inadomi J
Clin Gastroenterol Hepatol; 2020 Aug; 18(9):1961-1969. PubMed ID: 31816445
[TBL] [Abstract][Full Text] [Related]
9. Negative surveillance endoscopy occurs frequently in patients with short-segment non-dysplastic Barrett's esophagus.
Melson J; Desai V; Greenspan M; Yau S; Abdalla M; Dhanekula R; Mobarhan S; Shapiro D; Losurdo J; Jakate S
Dis Esophagus; 2015 Oct; 28(7):660-5. PubMed ID: 24943293
[TBL] [Abstract][Full Text] [Related]
10. Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer.
Streitz JM; Ellis FH; Tilden RL; Erickson RV
Am J Gastroenterol; 1998 Jun; 93(6):911-5. PubMed ID: 9647017
[TBL] [Abstract][Full Text] [Related]
11. The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis.
Omidvari AH; Hazelton WD; Lauren BN; Naber SK; Lee M; Ali A; Seguin C; Kong CY; Richmond E; Rubenstein JH; Luebeck GE; Inadomi JM; Hur C; Lansdorp-Vogelaar I
Gastroenterology; 2021 Aug; 161(2):487-494.e4. PubMed ID: 33974935
[TBL] [Abstract][Full Text] [Related]
12. The controversy regarding ablation for Barrett's esophagus without dysplasia.
Gaddam S; Muthusamy R; Sharma P
Curr Opin Gastroenterol; 2011 Jul; 27(4):368-73. PubMed ID: 21577102
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease.
Gerson LB; Groeneveld PW; Triadafilopoulos G
Clin Gastroenterol Hepatol; 2004 Oct; 2(10):868-79. PubMed ID: 15476150
[TBL] [Abstract][Full Text] [Related]
14. Surveillance in Barrett's esophagus: a failed premise.
Inadomi JM
Keio J Med; 2009 Mar; 58(1):12-8. PubMed ID: 19398879
[TBL] [Abstract][Full Text] [Related]
15. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus.
Das A; Wells C; Kim HJ; Fleischer DE; Crowell MD; Sharma VK
Endoscopy; 2009 May; 41(5):400-8. PubMed ID: 19418393
[TBL] [Abstract][Full Text] [Related]
16. Surveillance in Barrett's esophagus: an audit of practice.
Ajumobi A; Bahjri K; Jackson C; Griffin R
Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.
Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC
Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040
[TBL] [Abstract][Full Text] [Related]
18. A cost-effectiveness analysis of endoscopic eradication therapy for management of dysplasia arising in patients with Barrett's oesophagus in the United Kingdom.
Pollit V; Graham D; Leonard C; Filby A; McMaster J; Mealing SJ; Lovat LB; Haidry RJ
Curr Med Res Opin; 2019 May; 35(5):805-815. PubMed ID: 30479169
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of radiofrequency ablation for Barrett's esophagus with low-grade dysplasia: results from a randomized controlled trial (SURF trial).
Phoa KN; Rosmolen WD; Weusten BLAM; Bisschops R; Schoon EJ; Das S; Ragunath K; Fullarton G; DiPietro M; Ravi N; Tijssen JGP; Dijkgraaf MGW; Bergman JJGHM;
Gastrointest Endosc; 2017 Jul; 86(1):120-129.e2. PubMed ID: 27956164
[TBL] [Abstract][Full Text] [Related]
20. Use of Appropriate Surveillance for Patients With Nondysplastic Barrett's Esophagus.
Tavakkoli A; Appelman HD; Beer DG; Madiyal C; Khodadost M; Nofz K; Metko V; Elta G; Wang T; Rubenstein JH
Clin Gastroenterol Hepatol; 2018 Jun; 16(6):862-869.e3. PubMed ID: 29432922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
